Suven Pharmaceuticals reported 20.09% fall in net profit to Rs 109.46 crore on 11% decline in net sales to Rs 348.49 crore in Q3 FY23 over Q3 FY22.
Profit before tax shed by nearly 20% year on year to Rs 147.28 crore in the quarter ended 31 December 2022.EBITDA de-grew 18.29% to Rs 159.58 crore in the third quarter from Rs 195.30 crore reported in the same period last year. EBITDA margin slipped to 44.20% in Q3 FY23 as against 48.72% in Q3 FY22.
Total expenses rose marginally to Rs 213.71 crore while cost of materials consumed increased by 14.09% to Rs 135.16 crore during the period under review.
On consolidate basis, the pharma company's net profit slid 32.7% to Rs 107.72 crore on 9.66% decrease in net sales to Rs 353.77 crore in Q3 FY23 over Q3 FY22.
Suven Pharmaceuticals is in the business of Contract Development & Manufacturing Organisation (CDMO), catering to the needs of global pharma industry.
The scrip rose 1.11% to Rs 490.05 on the BSE.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
You’ve hit your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Quarterly Starter
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Access to Exclusive Premium Stories Online
Over 30 behind the paywall stories daily, handpicked by our editors for subscribers
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app